Connect with us
Eli Lilly will invest $3 billion to expand its Kenosha, Wisconsin, facility, acquired for $100 million in April. The site will manufacture injectable diabetes and obesity...
Sanofi will invest €1 billion in a new insulin factory in Beijing, its largest investment in China, citing demand from 140 million diabetic adults. This fourth...
Mason Capital, owning 2.1% of Grifols' Class A shares, seeks Tomás Dagá's resignation, citing governance concerns and shareholder value loss. The fund demands transparency on Dagá’s...
Leitat projects €48M in 2023 revenue, with 20% from R&D. Its health division, founded in 2009, specializes in therapies and health predictors, focusing on personalized medicine...
Spanish pharmaceutical stocks dropped 10% in November, led by Rovi's 17.5% plunge amid profit and turnover declines. Grifols also fell 16%, impacted by OPA cancellation and...
Gotham City raises doubts about Grifols following Brookfield's withdrawal from a takeover bid, claiming the firm lacked access to crucial data. Grifols shares dropped 14%, compounding...
Roche is acquiring Poseida Therapeutics for up to $1.5 billion, emphasizing its strategic focus on innovative allogeneic CAR-T cancer therapies. Poseida’s candidate P-BCMA-ALLO1 shows promise in...
Ysios Capital joined Adcendo's $135M Series B round, the EU's largest in biotech this year, enabling Adcendo to advance its cancer-targeting ADC pipeline. Based in Spain,...
Extremadura's biotech meeting aims to build a cohesive regional community to address global challenges through innovation. Focus areas include health, agriculture, and industry, showcasing local practices...
The biosimilars market is poised for growth driven by increased R&D investment, favorable regulations, and strategic industry partnerships. Key opportunities arise from the expiration of patents...